IRIS Phase-1
Financiado
A revolutionary blood test to easily diagnose and prevent deadly complications o...
A revolutionary blood test to easily diagnose and prevent deadly complications of organs and tissue transplants.
Transplantations are life-saving treatments, often representing the only option for people with severe disease such as blood
cancers. Unfortunately, complications linked to transplants are so high that they are current limiting th...
Transplantations are life-saving treatments, often representing the only option for people with severe disease such as blood
cancers. Unfortunately, complications linked to transplants are so high that they are current limiting the increase of adoption
of transplantations. Specifically, Graft versus Host Disease occurs in up to 80% cases after receiving bone marrow from a
donour and poses a serious threat to the life of patients already in critical condition. Graft versus Host Disease, today, can
only be suspected when it is already at an advanced state, i.e. when clinical symptoms appear. However, symptoms are not
unique, thus invasive biopsies are needed for a certain diagnosis. At this stage, even more time has been wasted before
starting an effective drug treatment: the mortality risk can reach 95%, the hospitalization period lasts months instead than
weeks and so drug treatments, that have to be stronger and more aggressive. MarxBio for the first time in the world was able
to link a particular enzyme called GSK-3beta to the onset of Graft versus Host Disease and, specifically, to the proliferation
of donor’s T-cells that attack the host. The Company has the unique knowhow to monitor the complex pathways of
GSK-3beta to diagnose and monitor the progression of the disease, through the use of tens of different, specific antibodies.
All of this know-how has been enclosed in a disposable protein chip, so a simple blood test, instead of a biopsy, is required
to detect the disease: results can be obtained in every laboratory, with the use of a standard fluorescence scanner. Scientific
results have been published and intellectual property has been protected with a patent portfolio. During Phase 1 project the
Company will assess the scale-up plan and the clinical trials to be conducted to validate the diagnostic kit, and will establish
a sound go-to-market strategy to ensure a swift market uptake of the proposed solution.
ver más
Duración del proyecto: 4 meses
Fecha Inicio: 2019-07-26
Fecha Fin: 2019-11-30
Fecha Fin: 2019-11-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2019-11-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
MARX BIOTECHNOLOGY LTD
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
273.77K€ |
Participante